ReviewThe Lancet regional health. Western Pacific2023
Towards elimination of cervical cancer - human papillomavirus (HPV) vaccination and cervical cancer screening in Asian National Cancer Centers Alliance (ANCCA) member countries.
Review in The Lancet regional health. Western Pacific, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Drivers of human papillomavirus vaccine uptake in migrant populations and interventions to improve coverage: a systematic review and meta-analysis.The Lancet. Public health · 2025Pooled it
- Human papillomavirus self-sampling in Asia: a systematic review.Frontiers in microbiology · 2025Pooled it
- Socioeconomic factors affecting breast and cervical cancer screening compliance in Asian National Cancer Centers Alliance countries: a systematic review.Epidemiology and health · 2025Pooled it
- Addressing HPV vaccine hesitancy and misinformation in India through public health communication strategies.Human vaccines & immunotherapeutics · 2026Article
- Infection-driven cancers in Asia: implications from epidemiological transitions.The Lancet regional health. Western Pacific · 2026Review
- Analyzing and forecasting global cervical cancer burden based on WHO's elimination strategy: insights and projections from a 1990-2021 global burden of disease (GBD) study covering 204 countries and territories.Journal of advanced research · 2026Article
- Establishment and genomic characterization of patient-derived organoids from gastric-type cervical adenocarcinoma.Journal of gynecologic oncology · 2026Article
- Systemic immune-inflammatory index for the prediction of the survival in patients with cervical cancer: A meta-analysis.iScience · 2026Article
- Evaluation of results from KEYNOTE-826 and its impact within the East Asian population with real-world applications.Gynecology and pelvic medicine · 2026Article
- Unveiling the ZNF384-INTS13-hnRNPC axis as a therapeutic vulnerability in cervical cancer.Cell death & disease · 2025Article
- Cervical cancer burden and trends in China, 2000-2020: Asia-Pacific international comparisons and insights for elimination goals.Cancer biology & medicine · 2025Article
- Bangkok declarations on cancer control in Asia.The Lancet regional health. Western Pacific · 2025Review
- HPV infection trends in Inner Mongolia across the pre- and pandemic periods of COVID-19: A single-center analysis.Medicine · 2025Article
- Identifying Predictors of Cervical Cancer Screening Uptake in Sub-Saharan Africa Using Machine Learning: Cross-Sectional Study.JMIR public health and surveillance · 2025Article
- Challenges in Expanding Access to the HPV Vaccine Among Schooling Girls: A Mixed-Methods Study from Indonesia.Vaccines · 2025Article
- The Utilization of Human Papillomavirus Testing for Cervical Cancer Screening in Thailand: A Comparison of Screening with and without Self-sampling Samples.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- College Students' Knowledge, Attitudes, and Practices on Cervical Cancer Prevention in India.Cureus · 2025Article
- Monitoring the presence of human papillomavirus in public areas indicates non-sexual transmission of the virus and environmental risk.BMC public health · 2025Article
- Advancing Cervical Cancer Prevention Equity: Innovations in Self-Sampling and Digital Health Technologies Across Healthcare Settings.Diagnostics (Basel, Switzerland) · 2025Review
- Interleukins in the Pathogenesis of Warts: Insight from the Last Decade-A Narrative Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 20 institutions in 20 countries.
Funding
Abstract
About 95% of cervical cancers worldwide are caused by human papillomavirus (HPV). Cervical cancer is preventable and curable if it is detected and treated early. We reviewed the latest national cervical cancer indicators, and barriers to HPV vaccination and cervical cancer screening in 21 Asian National Cancer Centers Alliance (ANCCA) member countries. Half (n = 11, 52%) of the countries have introduced HPV vaccination for girls as part of their national vaccination programme, three countries reported coverage of over 90%. Most ANCCA member countries have cervical cancer screening programmes, only five countries reported screening uptake of over 50%. The barriers to HPV vaccination coverage and cervical cancer screening participation have been identified. Ensuring health service accessibility and affordability for women, addressing sociocultural barriers, and strengthening the healthcare system and continuum of care are essential to increase HPV vaccination and cervical cancer screening coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.